Messoud Ashina, AAN 2021: Atogepant as a Preventative Option for Migraine

We were delighted to meet with Messoud Ashina (University of Copenhagen, Copenhagen, Denmark) to discuss the long term safety and tolerability profile of atogepant, and its place as a preventative option for migraine.

The abstract entitled: ‘Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.

Questions:

1. What has the study taught us about the long term safety and tolerability profile of atogepant? (0:14)

2. What place is atogepant likely to play in the preventative treatment paradigm for migraine? (3:01)

Disclosures: Messoud Ashina has received personal fees from AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis and Teva; is the principal investigator for AbbVie/Allergan, Amgen, Eli Lilly and Lundbeck in ongoing clinical trials; has received Research grants form Lundbeck Foundation, Novo Nordisk Foundation, and Novartis; has no ownership interest and does not own stocks of any pharmaceutical company. Messoud Ashina is also an Associate Editor of Cephalalgia and associate editor of the Journal of Headache and Pain, and is the President of the International Headache Society.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of AAN Annual Virtual Meeting 2021.